Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Dual-targeting of B & T Cell Pathways Evaluation Trial (DUET)

12 novembre 2026 aggiornato da: Diabetes Free, Inc.

Evaluation of Safety, Treatment Response and Biological Effects of DFI205 in Systemic Autoimmune Rheumatic Diseases (SARDs); a Phase 1/2a First-in-Human (FIH) Study

This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

72

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Male and female participants, age 18 years and older.
  • Able to understand and comply with all scheduled visits, treatment plans, laboratory tests, and other procedures of the study protocol including ability to provide written informed consent.
  • Maintaining a stable, qualifying, standard of care regimen for ≥4 weeks prior to screening as treatment for a qualifying primary diagnosis (RA, SLE, SSc, IIM including the disease-specific criteria listed below):
  • Rheumatoid Arthritis (RA) participants must have, 1) positivity of anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor (RF); 2) moderate to highly active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months; secondary Sjögren's disease diagnosis is acceptable as long as other criteria are met.
  • Systemic Lupus Erythematosus (SLE) participants must have, 1) positivity of anti-nuclear-antibodies (ANA) and/or anti-dsDNA and/or anti-histone and/or anti-nucleosome and/or anti-Sm antibodies; 2) active disease despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months.
  • Systemic Sclerosis (SSc) participants must have, 1) positivity for at least one SSc-associated autoantibody; 2) mRSS score >10 units or interstitial lung disease (ILD) including clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≤ 5 years (from onset of first non-Raynaud manifestation); 4) not eligible for or declining autologous hematopoietic stem-cell transplantation
  • Idiopathic Inflammatory Myopathies (IIM) participants must have, 1) positivity for at least one myositis-specific antibody; 2) active myositis or presence of ILD defined by clinically relevant pulmonary involvement despite treatment with at least 2 lines of standard therapy; 3) disease duration ≥ 6 months

Exclusion Criteria:

  • Diagnosis of a non-rheumatic autoimmune disease requiring therapeutic or investigational immune therapy or modulation (e.g., neuropathy requiring IVIg, Multiple Sclerosis). Milder autoimmune conditions requiring replacement or exocrine functional therapies are acceptable (e.g., Type 1 diabetes, Celiac Disease, Autoimmune Thyroid Disease if on stable treatment for at least 6 months).
  • History of any pre-existing liver disease, including cirrhosis, acute liver disease, or chronic liver disease (unless considered stable for >6 months and required screening laboratory tests meet criteria).
  • Severe unresolved cardiac disease.
  • Estimated glomerular filtration rate (GFR) <30 mL/min/1.73 m2.
  • Presence or history of active infections, including hepatitis B, hepatitis C, human immunodeficiency virus (HIV), Human T-lymphotropic virus (HTLV) or tuberculosis. Participants with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection. Participants with mild skin and nail fungal infections are not excluded.
  • Acute infection requiring systemic therapy or hospitalization within 30 days before screening.
  • Invasive aspergillus, histoplasmosis, or coccidioidomycosis infection within one year prior to enrollment.
  • Any history of malignancy in the 5 years before screening except for completely resected squamous or basal cell carcinoma of the skin.
  • Primary or secondary immunodeficiency, including hypogammaglobulinemia.
  • History or evidence of progressive multifocal leukoencephalopathy (PML) or other demyelinating disorders.
  • Allergies to humanized monoclonal antibodies or severe post-treatment hypersensitivity reactions other than localized injection site reaction, to any biological molecule.
  • Systemic corticosteroid therapy or adrenocorticotropic hormone (ACTH) use within 30 days prior to screening and within entire duration of screening period prior to beginning of study treatment, unless prescribed as background therapy.
  • Intolerance of or contraindication to oral or IV corticosteroids.
  • Treatment with other biologic or non-biologic immunosuppressant agents (e.g., anti-CD20 therapies, TNF inhibitors, azathioprine, cyclosporine, methotrexate, or mycophenolate) within 6 months prior to screening, unless prescribed as background therapy.
  • The participant has taken another investigational drug within 3 months or 5-half-lives before the screening visit, whichever is longer, or any investigational drug that has depleted a cell type or line without recovery.
  • Previous treatment with anti-CD19 agents, anti-CD38 agents, bispecific anti-CD19/CD3 T cell engaging therapies, adoptive T cell therapy or any prior gene therapy product.
  • Received any form of stem cell transplant.
  • Administration of live attenuated vaccine(s) within 12 weeks prior to and 12 weeks after the completion of DFI205 administration or any planned receipt during the study that cannot be delayed. Vaccinations should be up-to-date as per local clinical practice.
  • Plasmapheresis within 3 months prior to first dose of DFI205
  • Positive pregnancy test, presently breast-feeding, (female participants) or unwillingness to use highly effective contraceptive measures for the duration of the study and 6 months after discontinuation.
  • Any condition, including the presence of relevant abnormalities in vital parameters or laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Phase 1 Single Ascending Dose Escalation

Intravenous (IV) infusion of DFI205 at ascending dose levels.

A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.

Sperimentale: Phase 2a Multi-Dose

DFI205 monthly IV infusions at the recommended Phase 2 dose

A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To evaluate the initial safety and tolerability of DFI205 in adults with SARDs
Lasso di tempo: Up to 1 year post-dosing

Numbers and types of all adverse events (AEs) and serious adverse events (SAEs)

Up to 1 year post-dosing
To monitor immune reconstitution after completion of dosing with DFI205
Lasso di tempo: Up to 1 year post-dosing

Time to normalized peripheral blood B cell counts compared to baseline.

Up to 1 year post-dosing
To monitor immune response to DFI205
Lasso di tempo: Up to 1 year post-dosing

Number of participants with anti-drug antibody development.

Up to 1 year post-dosing

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
To evaluate the ability of DFI205 to induce an objective response in adults with RA
Lasso di tempo: 24 weeks post-dosing

Overall Response Rate (ORR) measured by proportion of participants achieving either low-disease activity (DAS28-CRP ≤ 3.2, DAS28-ESR ≤3.2, SDAI≤11, CDAI≤10) or remission criteria (DAS28-CRP < 2.6, DAS28-ESR <2.6, SDAI ≤3.3, CDAI ≤ 2.8,Boolean 2.0 remission criteria) combined

24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with SLE
Lasso di tempo: 24 weeks post-dosing

Overall Response Rate (ORR) measured by fulfillment of DORIS remission criteria

24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with SSc
Lasso di tempo: 24 weeks post-dosing

Overall Response Rate (ORR) measured by proportion of participants achieving either modified Rodnan Skin Score (mRSS) decrease of >5 points and ≥ 25% decrease from baseline or no progression of interstitial lung disease (ILD progression defined as FVC decline >10%, or 5-10% plus worsening respiratory symptoms or HRCT progression) combined

24 weeks post-dosing
To evaluate the ability of DFI205 to induce an objective response in adults with IIM
Lasso di tempo: 24 weeks post-dosing

Overall Response Rate (ORR) measured by achievement of major response (ACR/EULAR 2016 Myositis Response Criteria Total Improvement Score ≥ 60)

24 weeks post-dosing

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Lasso di tempo: 24 weeks post-dosing

Change in tender joint count (TJC28) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with RA
Lasso di tempo: 24 weeks post-dosing

Change in swollen joint count (SJC28) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with SLE
Lasso di tempo: 24 weeks post-dosing

Change in British Isles Lupus Assessment Group (BILAG-2004) score compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with SSc
Lasso di tempo: 24 weeks post-dosing

Change in mRSS (0=no thickening, 3=severe thickening) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Lasso di tempo: 24 weeks post-dosing

Change in creatine phosphokinase (CPK) compared to baseline

24 weeks post-dosing
To evaluate the ability of DFI205 to reduce disease activity in adults with IIM
Lasso di tempo: 24 weeks post-dosing

Change in muscle strength (MMT8 score) compared to baseline

24 weeks post-dosing
To evaluate change in erythrocyte sedimentation rate (ESR) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Lasso di tempo: Up to 1 year post-dosing
Up to 1 year post-dosing
To evaluate change in C-reactive protein (CRP) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Lasso di tempo: Up to 1 year post-dosing
Up to 1 year post-dosing
To evaluate change in interleukin-6 (IL-6) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Lasso di tempo: Up to 1 year post-dosing
Up to 1 year post-dosing
To evaluate change in tumor necrosis factor-alpha (TNF-α) as a potential biomarker of progression/treatment response to DFI205 over the course of the study.
Lasso di tempo: Up to 1 year post-dosing
Up to 1 year post-dosing
To investigate the pharmacokinetics of DFI205
Lasso di tempo: Up to 1 year post-dosing

Blood samples will be collected to quantitate serum concentrations of DFI205

Up to 1 year post-dosing
To investigate the pharmacodynamics of DFI205 in blood
Lasso di tempo: Up to 1 year post-dosing

Proportions of immune cell subsets in blood by FACS analysis over the course of the study.

Up to 1 year post-dosing
To investigate the secondary lymphoid system pharmacodynamics of DFI205
Lasso di tempo: Up to 1 year post-dosing

Proportions of disease-specific lymph node cell populations over the course of the study.

Up to 1 year post-dosing
To investigate soluble CD40 pharmacodynamics of DFI205
Lasso di tempo: Up to 1 year post-dosing

Soluble CD40 receptor/ligand blood concentrations over the course of the study treatments.

Up to 1 year post-dosing

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Georg Schett, M.D., University of Erlangen-Nürnberg

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

1 agosto 2028

Completamento dello studio (Stimato)

1 dicembre 2028

Date di iscrizione allo studio

Primo inviato

3 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2026TXSARD01
  • 2026-526672-24-00 (Ctis)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .